## In the Abstract

## Kindly replace the Abstract with the following:

The invention relates to the use of a compound that transitorily depletes or inhibits B lymphocytes in the preparation of a composition for being administered to a patient in order to augment the specific T cell response to a vaccine, in particular a therapeutic vaccine, against a tumor or a chronic infection by a virus, a parasite or some other microorganismA method of amplifying activity of therapeutic vaccines including administering an effective amount of a composition including a compound that depletes or inhibits B lymphocytes to a patient sufficiently to amplify an immune reaction of T cytotoxic lymphocytes. In a particular use the The composition is tomay be administered to a patient in order to augment the specific T cell response to a vaccine, in particular, a therapeutic vaccine, eomprising including at least one inactivated human immunodeficiency virus (HIV). In particular, the depleting compound [[is]]may be an antibody, advantageously monoclonal, directed against transmembrane antigen CD20 of pre-B or mature B lymphocytes.